57 results about "Thrombin time" patented technology

A system and method for determining a coagulation time, e.g., thrombin time, PT, aPTT, and ACT, of a blood sample deposited in a test cartridge is disclosed. The test cartridge comprises a blood receptacle that is open to the atmosphere into which a blood sample is to be deposited, a vacuum port that is open to atmosphere, and a spiral capillary within the test cartridge having a capillary length and cross-section area, a first capillary end of the spiral capillary open to the blood receptacle and a second capillary end of the spiral capillary open to the vacuum port, whereby the spiral capillary is closed to atmosphere. When a blood sample is deposited in the blood receptacle, a vacuum is drawn through the vacuum port and the blood is drawn through the spiral capillary until coagulation occurs. A pressure change is detected, and the coagulation time is measured.

The invention discloses a method for evaluating chemical composition of Rosa xanthina on the basis of antithrombotic spectrum-effect relationship. The method comprises the following steps: preparing extract of different polar components of the Rosa xanthina with a modern separation technology; establishing fingerprint of extract of each component with high-performance liquid chromatography, and calibrating characteristic peaks; evaluating antithrombotic activity of different extract on the basis of platelet aggregation inhibition rate, prothrombin time, thrombin time and activated partial thromboplastin time as indexes; substituting fingerprint characteristic peak data and pharmacodynamical activity data into a mathematical model for spectrum-effect correlation analysis, and evaluating pharmacodynamical activity of the characteristic peaks. With adoption of the method for evaluating the chemical composition of the Rosa xanthina on the basis of the antithrombotic spectrum-effect relationship, the antithrombotic chemical composition in the Rosa xanthina can be evaluated rapidly and accurately, a scientific and effective method is provided for research of pharmacodynamic material basis and quality control of the Rosa xanthina, and reference is provided for further development of Rosa xanthina drugs or health care products for treating thrombotic diseases.

The invention relates to a preparation of anti-coagulation dermis scaffold which is used for skin injury repair and has good three-dimensional porous structure. The scaffold preparation uses three natural biologicals of regeneration silk fibroin, chitosan and heparin as raw materials, wherein, heparin has outstanding anti-coagulation property. The dermis scaffold has high porosity and aperture size appropriate for dermal cells to grow; the scaffold has better mechanical property and good hydrophily; the artificial dermis scaffold has heparin slow release function, so that the protrombin time, partial thromboplastin time and thrombin time thereof can be obviously prolonged, thus proving that the dermis scaffold has excellent anti-coagulation property.

The invention provides a terpenoid shown by the formula I or pharmaceutically acceptable salt, ester or hydrate thereof. The invention also provides a preparation and application of the terpenoid. In the invention, a carbon-drop diterpene new compound separated from leonurus is carbon-drop labdane diterpene obtained from the nature for the first time. The compound can obviously shorten the PT (prothrombin time), APTT (activated partial thromboplastin time) and TT (thrombin time) in vitro and obviously increase the amount of FIB (fibrinogen) in blood, and realizes a certain effect on enhancing the coagulation function, thereby providing a new option for developing a novel natural coagulation drug.

The invention discloses application of a peptide compound in rhizoma sparganii in the preparation of medicines for resisting blood coagulation and/or thrombus. The structural formula of the peptide compound is as shown in a formula (I). The invention provides the peptide compound obtained from the rhizoma sparganii through the separation and the purification and the application thereof for the first time. The peptide compound has an elongation tendency effect on prothrombin time (PT), activated partial thromboplastin time (APPT) and thrombin time (TT) and very good anticoagulation activity and provides powerful basis for the development of antithrombus natural medicines.

The invention discloses applications of a peptides compound in rhizome sparganii in preparing anticoagulant and/or antithrombosis medicaments. The structural formula of the peptides compound is shown in the formula (I). The peptides compound obtained by separating and purifying rhizome sparganii, and applications thereof are provided for the first time, the compound plays a role in prolonging the prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT), has good anticoagulation activity, and provides a powerful basis for developing natural antithrombosis medicaments. The formula (I) is as shown in the specification.

The invention discloses a liquid-type prothrombin time detection reagent and a preparation method thereof. The preparation method comprises the following steps: dissolving amino acid, polyethylene glycol, mannitol, bovine serum albumin, and gelatin in water so as to obtain a prothrombin protective fluid, and adjusting the pH value of the prothrombin protective fluid to 6.0-8.0; and dissolving prothrombin freeze-dried powder in the prothrombin protective fluid so as to obtain the liquid-type prothrombin time detection reagent, wherein the enzymatic activity of the liquid-type prothrombin time detection reagent is 5-80 IU/mL. The liquid-type prothrombin time detection reagent contains prothrombin, amino acid, polyethylene glycol, mannitol, bovine serum albumin and gelatin, and takes water as a solvent. The production process of the reagent disclosed by the invention is simplified, production facilities are simple, no freeze-drying process is performed, and the production cost is low; the reagent is used in an out-of-the-box mode; the variation among bottles is small; and the reagent is high in stability.

The present invention is directed to a sensor with opposing electrodes and test strips using this sensor. The invention can be used to measure blood or plasma coagulation in assays like prothrombin time (PT) and thrombin potential, for example, in point-of-care monitoring of anticoagulants.

The invention discloses an application of an active peptide compound in rhizoma sparganii to the preparation of anticoagulant and/or antithrombotic drugs. The active peptide compound has the structural formula (I) shown in the specification. The invention firstly provides the peptide compound obtained from the rhizoma sparganii by separating and purifying and the application of the peptide compound. The compound has a trend prolonging effect for the prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT), has favorable anticoagulation activity and provides a powerful basis for the development of natural antithrombotic drugs.

The invention belongs to the field of biotechnology, and especially relates to a thrombin time detection reagent. The thrombin time detection reagent comprises thrombin, HEPES, NaN3, peptone, and calcium chloride. Ca2+ is added into a buffer solution to stimulate in vivo blood coagulation environment based on study on reaction mechanism, so that the thrombin time detection reagent is relatively high in clinical application value. The buffer solution ingredient in the thrombin time detection reagent is capable of realizing stabilization of thrombin reagent for 7 days after redissolving at 37 DEG C, and the stability of the thrombin time detection reagent is higher than that of commercially available reagents. In hospitals of different levels, the thrombin time detection reagent is reliable and convenient to use, waste is reduced, and medical cost is reduced.

The invention relates to comb shell viscera polysaccharide, an extraction method and application thereof, and a drug composition. The main chain of the comb shell viscera polysaccharide is -6)Manp(1-3)Galp(1-, wherein -SO4 exists in C-4 of Man (1- and/or C-4 site of -3Gal(1-. The polysaccharide has the effect of inhibiting thrombin to catalyze the activity of thrombin fibrinogen, can prolong activated partial thromboplastin time (APTT) and thrombin time (TT), and has no obvious influence on the prothrombin time (PT).

The invention relates to a blood clotting time test analysis method, especially relates to thrombin time test, and belongs to the technical field of blood clotting test analysis. The blood clotting time test analysis method is characterized in that a test piece (22) is provided with a blood sample accommodating cavity, a reagent accommodating cavity and a capillary channel (3) coated with a conductive layer (5); and the blood sample accommodating cavity, the reagent accommodating cavity and the capillary channel (3) coated with the conductive layer (5) are sequentially interconnected, a mixed liquid obtained after mixing a blood sample with a reagent flows to the capillary channel (3), the resistance of the conductive layer (5) changes with the flow of the mixed liquid, and the resistance changing stop time point is obtained to measure the time required by blood clotting. The method has the advantages of ingenious design, great improvement of the visual degree of a measurement result, great reduction of requirements of a test device, reduction of the test cost and threshold, convenience for use in outpatient departments and below county level small medical units, and convenience for gradual promotion of use in patients' homes.

The invention discloses a stabilizer, a thrombin time test reagent, a preparation method of the thrombin time test reagent and a kit. The stabilizer comprises xanthan gum, and the thrombin time test reagent comprises thrombin, a buffer solution and the stabilizer. The stabilizer comprises xanthan gum, the concentration of the xanthan gum in the thrombin time test reagent is 0.1g/L to 10g/L, and the enzyme activity of thrombin is 1IU/mL to 50IU/mL. The stability of the liquid thrombin time test reagent is remarkably improved by utilizing a network structure of xanthan gum macromolecules.

The invention relates to a liquid thrombin time detection reagent and belongs to the field of medical in vitro diagnosis. The liquid thrombin time detection reagent disclosed by the invention consistsof the following components: 2 to 4U/mL of bovine thrombin; 10 to 66mM of Tris; 0.1 to 3% of gelatin, 0.1 to 2% of PEG 6000; 0.1 to 5% of BSA; 0.1 to 1.5% of sodium chloride, 2mM to 12mM of benzamidine hydrochloride; 0.05 to 0.3% of preservative ProClin300; and the balance of water. The invention provides the liquid thrombin time detection reagent by researching a blood coagulation reaction mechanism; the detection reagent adopts a unique buffer system to stabilize the activity of thrombin, so that the thrombin time detection reagent is higher in stability and repeatability verification accuracy and convenient for clinical application, reduces medical cost, is mutually beneficial for medical treatment and diseases and avoids resource waste. The liquid thrombin time detection reagent disclosed by the invention is applied to existance of an anticoagulant material or fibrinogen dissolving system abnormality and blood coagulation abnormality monitoring treatment, and finally, the thrombinliquid reagent is widely applied to clinical detection, so that thrombin time detection is more convenient, accurate and standardized.

The invention relates to application of glaucocalyxin A and particularly relates to application of glaucocalyxin A in preparation of anticoagulation medicaments. The glaucocalyxin A can be used for remarkably prolonging the capillary coagulation time and tail tip bleeding time of mice, and remarkably prolonging the thrombin time (TT), prothrombin time (PT), activated partial thromboplastin time (APTT) and plasma recalcification time (PRT) of the mice. The glaucocalyxin A can be used for remarkably prolonging the TT, APTT and PRT for domestic rabbits in vitro. The results of in-vivo-administration anticoagulation experiments prove that the glaucocalyxin A can be used for remarkably prolonging the APTT and PRT of the mice, thereby prompting that the glaucocalyxin A can be used for inhibiting the generation of fibrin by disturbing intrinsic coagulation factor activity; and the remarkable prolonging of the TT proves the inhibition of transformation from fibrinogen to fibrin. The results of the in-vivo-administration anticoagulation experiments also prove that the glaucocalyxin A has a certain inhibition effect on extrinsic coagulation pathways since the glaucocalyxin A can be used for remarkably prolonging the PT. The results of in-vitro experiments prove that the glaucocalyxin A can be used for remarkably prolonging the APTT, PT and PRT, but has no obvious effects on the PT, thereby proving that the glaucocalyxin A realizes the anticoagulation effect in vitro mainly through inhibiting intrinsic coagulation pathways.

The invention discloses a thrombin time detection reagent. The thrombin time detection reagent comprises components with the following contents: 1U/mL to 10U/mL of bovine thrombin, 0.24wt% to 1.2wt% of 4-hydroxyethylpiperazine ethane sulfonic acid, 0.5wt% to 2wt% of bovine serum albumin, 0.1wt% to 0.3wt% of a proclin300 preservative, 0.3wt% to 2wt% of inorganic sodium salt, 0.8wt% to 2wt% of non-polar glycine, 0.2wt% to 2wt% of sugar alcohol, 0.2wt% to 0.5wt% of polysaccharide and the remaining amount of water. The invention also discloses a preparation method of the thrombin time detection reagent. The thrombin time detection reagent prepared by the invention is good in reproducibility and high in stability, also has high correlation with the listed thrombin time detection reagent, and can improve the stability of the thrombin time detection results.

The invention relates to an expression preparation method and application of a novel anticoagulant Aedes albopictus salivary gland aegyptin-like protein ALP. The method comprises the following step: 1, carrying out optimized synthesis of ALP mature peptide DNA; 2, constructing a recombinant plasmid pPICZalphaA-ALP; and 3, expressing and purifying a recombinant protein ALP. The method uses the ALP protein expressed by a pichia yeast expression system (pPICZalphaA-ALP X33) of a pPICZalphaA vector in order to realize correct secretion and expression, and the purified ALP protein has anticoagulation activity, can substantially prolong the prothrombin time (PT), the thrombin time (TT) and the activated partial thromboplastin time (APTT) in vitro, can be used as a novel anticoagulant, and lays a research foundation for research of the feasibility of the purified ALP protein as a novel anticoagulant for preventing and treating thrombotic diseases and other vascular diseases, so the method has positive social benefit and substantial economic benefit if the method is widely proved and clinically used.

The invention belongs to the technical field of microbial secondary metabolite applications and particularly relates to the application of cochliodinol, as a chaetomium spirale strain secondary metabolite, in preparing anticoagulant drugs. The chaetomium spirale strain generates a large number of secondary metabolites based on its own unique biosynthetic pathway, so that the industrial production can be achieved. Meanwhile, the sustainable development is enabled. The TT ((i) p & < 0.001 (i)) can be significantly prolonged by the cochliodinol. Meanwhile, the FIB ((i) p & < 0.001 ( i)) can be significantly reduced by the cochliodinol. Therefore, the blood coagulation can be inhibited through prolonging the thrombin time and reducing the content of fibrinogen in the plasma. The cochliodinol has a potential value for the development of anticoagulant drugs.

The invention relates to a blood sample analysis and test system which is used for detecting blood coagulation parameters of a blood sample and comprises prothrombin time (PT), fibrinogen quantitative determination (FTB), activating part thromboplastin time (APTT), thrombin time (TT) and the like, wherein aiming at detection reagents in different batches, a standard quality control product is used for correcting a blood coagulation reaction curve, so that the batch-to-batch precision of the detection reagents can be improved, and the accuracy of the detection result is improved.